What is the relationship between memory and thinking ability, brain scans (pictures
of the brain), genetics, blood and brain-spinal fluid features and the progression
of Alzheimer's disease (AD)?
Basic Study Information
Purpose:Location: AD-CARE at Monroe Community Hospital; 435 East Henrietta Rd., Rochester, NY 14620
ADNI3 is not a treatment study. It continues research that began in 2004 (ADNI1) and
will follow people over a five year period using the information collected from thinking
and memory testing, brain imaging, genetics testing, and blood and brain-spinal fluid
testing to help improve the way AD research is conducted. Approximately 1070 - 2000
participants will be enrolled at 59 sites in the US and Canada. Three groups will
be enrolled and evaluated: those with normal thinking and memory, those with mild
cognition problems, and those with mild Alzheimer's disease. The normal thinking cohort
is filled; the study is now only recruiting people with mild cognition problems (MCI)
or mild Alzheimer's disease.
Study Web URL: http://ADNI3.org
Study Reference #: 64311
Lead Researcher (Principal Investigator)
Lead Researcher: Anton Porsteinsson
Study Contact InformationStudy Coordinator: Nancy Kowalski, MS, RN
Phone: (585) 760-6569
Additional Study Details
If you are eligible to participate, your participation in this study will last 3 to
5 years, depending on which group you fit in. MCI participants will come to the clinic
every year for up to 5 years. Mild AD participants will come to the clinic every year
for 3 years and then will participate in annual phone checks. Visits will include
thinking and memory tests, collecting blood samples and brain imaging (MRI & PET scans).
Some visits will include collecting cerebrospinal fluid (CSF) by lumbar puncture.
Number of Visits:
6 to 10
Learn More About These Conditions
More information about Alzheimer's disease
Trial Not Found
The study you are looking for is not active at this time.
Return to Search